A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer

NCT02182063 | Completed Phase 2

• 1 other identifier: 1199.11
• Study Type: interventional
• Target: 81
• Locations: 0 countries
• Sites: N/A

Brief Summary

The aim of this study was to evaluate the efficacy of two different doses of BIBF 1120 (250 mg twice daily versus 150 mg twice daily) in an exploratory manner. Safety, quality of life and pharmacokinetic parameters on a sub-sample of 20 patients were also analysed for the two different doses.

Conditions

Prostatic Neoplasms

Outcome Measures

Primary Outcomes (1)

• Decline of prostate specific antigen (PSA) of ≥20%

  Up to week 25 after first drug administration

Secondary Outcomes (10)

• Decline of prostate specific antigen (PSA) of ≥50%

  Up to week 25 after first drug administration

• Time to Tumour Progression (TTP)

  Up to week 29

• Incidence and intensity of Adverse Events

  Up to week 34

• Radiological response rate according RECIST (Response Evaluation Criteria in Solid Tumours)

  Up to week 25 after first drug administration

• Change in Eastern Cooperative Oncology Group (ECOG) performance status

  Baseline, up to week 25

Study Arms (2)

BIBF 1120 low dose

EXPERIMENTAL

Drug: BIBF 1120 low dose

BIBF 1120 high dose

EXPERIMENTAL

Drug: BIBF 1120 high dose

Interventions

BIBF 1120 low dose DRUG

BIBF 1120 low dose

BIBF 1120 high dose DRUG

BIBF 1120 high dose

Eligibility Criteria

• Sex: male
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient written informed consent obtained prior to any study procedures and consistent with ICH-GCP (International Conference on Harmonization - Good Clinical Practice) guidelines and local law
• Presence of histologically documented adenocarcinoma of the prostate
• Presence of metastatic disease
• Life expectancy of at least 3 months
• Progression after orchidectomy or during LH-RH (Luteinising hormone - releasing hormone) analogs with castrate testosterone serum levels \<30 ng/ml (chemical castration had to be continued) and absence of anti-androgen withdrawal syndrome
• Minimum value of PSA = 20 ng/ml at screening
• ECOG performance status ≤ 2
• Progression after only one previous chemotherapy with docetaxel based regimen:
• Appearance of a new lesion or increase of an existing measurable / non measurable lesion
• Increase of PSA ≥ 25% documented by two successive exams
• Increase of pain if there is a correlation with a radiological progression or with a PSA increase as defined above
• Adequate hepatic function: total bilirubin within normal limits, ALT (Alanine aminotransferase) and/or AST (aspartate aminotransferase) ≤ 1.5x upper limit of normal (ULN). Prothrombin time (PT) and partial thromboplastin time (PTT): maximum 50% deviation from normal limits
• Adequate renal function: serum creatinine ≤ 2 x upper normal limit (UNL)
• Absolute neutrophil count (ANC) ≥ 1500/mL, Platelets ≥ 100,000/mL, Hemoglobin ≥ 9.0 g/dL (hemoglobin may be supported by transfusion or erythropoietin or other approved hematopoietic growth factors)

You may not qualify if:

• Gastrointestinal disorders or abnormalities that would inhibit absorption of the study drug
• Serious illness or concomitant non-oncological disease such as neurologic-, psychiatric-, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study
• Significant cardiovascular diseases (i.e. uncontrolled hypertension, instable angina, history of myocardial infarction or congestive heart failure \>NYHA II (New York Heart Association) during the 6 previous months
• Strontium or equivalent radioactive isotope during the 6 previous months
• Concomitant second malignancy, with the exception of treated basal cell carcinoma of the skin or a recovered cancer at least since 5 years
• Major injuries and surgeries within the past 4 weeks. Planned surgical procedures during the trial. Patients with incomplete wound healing
• History of haemorrhagic or emerging thrombotic event. Known inherited predisposition to hemorrhage or thrombosis
• Patients who require full-dose anticoagulation or heparinization or continuous treatment with acetylsalicyclic acid \> 325 mg
• Concomitant treatment with other experimental drugs or anti-cancer therapy including hormone therapy (except LH-RH agonists)
• Known or suspected symptomatic brain metastases
• Known or suspected symptomatic epiduritis
• Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy (visit 2) or concomitantly with this trial
• Patients unable to comply with the protocol

Sponsors & Collaborators

• Boehringer Ingelheim: lead

Related Links

• Related Info

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

nintedanib

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 2, 2014
• First Posted: July 8, 2014
• Study Start: November 1, 2005
• Primary Completion: January 1, 2007
• Last Updated: December 28, 2017

Record last verified: 2017-12